Search results
Added:
7 months ago
Source:
Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide…
View more
Added:
2 weeks ago
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and…
View more
Added:
2 weeks ago
Source:
Cardiac Failure Review
The optimal timing for complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease who also present with heart failure is a key clinical question. A pre-specified subgroup analysis of the OPTION-STEMI trial suggests that a staged approach may be preferable to immediate complete revascularisation in this high-risk patient group…
View more
Added:
2 weeks ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
The role of long-term beta-blocker therapy following a myocardial infarction (MI) in patients without heart failure remains a subject of clinical debate, particularly in the modern era of reperfusion and secondary prevention. The BETAMI–DANBLOCK trial sought to address this evidence gap by evaluating the efficacy of beta-blockers in this specific patient population.¹BETAMI–DANBLOCK was an open…
View more
Added:
1 month ago
Source:
Radcliffe Cardiology
The routine use of beta-blockers following myocardial infarction (MI) in patients with a preserved ejection fraction has been a topic of clinical uncertainty. A new large-scale, individual-patient data meta-analysis from the Beta-Blocker Trialists’ Collaboration Study Group, combining five major trials, has found no significant benefit for this patient population.¹MethodologyThis meta-analysis…
View more
Added:
2 years ago
AHA 2023 — Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) sat down with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the SELECT trial (NCT03574597).In this randomized, double-blind, parallel-group, placebo-controlled trial sponsored by Novo Nordisk, semaglutide was compared with a placebo in patients who have overweight or obesity and a history of…
View more
Added:
7 months ago
Source:
Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac…
View more
Added:
1 year ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants…
View more
Added:
1 year ago
THT Conference 2025 - Positive safety and efficacy outcomes were found of the Reprieve decongestion management system (DMS; Reprieve Cardiovascular, Inc) for the treatment of acute decompensated heart failure (ADHF). Urinary sodium excretion was seen to be significantly higher in the Reprieve DMS arm than in the control arm, and there were fewer UTI infections in ADHF patients receiving the…
View more